Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
InvestorService: Genmab, Named Finalist for Investor Relations Excellence Award5 Jul 2006
Genmab, AMG 714 Phase II Results Presented at EULAR Conference22 Jun 2006
Genmab, Grant of Warrants in Genmab A/S - Correction22 Jun 2006
Genmab, Corrected AMG 714 Phase II Results22 Jun 2006
Genmab, Grant of Warrants in Genmab A/S21 Jun 2006
Genmab, Grant of Warrants in Genmab A/S21 Jun 2006
InvestorService: Genmab, to Present at Two Investor Conferences12 Jun 2006
Genmab, HuMax-CD38 Shows Unique Property in Preclinical Studies
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
8 Jun 2006
Genmab, insiders' tradings8 Jun 2006
Genmab, articles of association dated May 30, 20067 Jun 2006
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise30 May 2006
Genmab, insiders' tradings30 May 2006
  • Previous
  • 1
  • More pages
  • 126
  • 127
  • 128
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863